Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract B116: Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS

Mol Cancer Ther (2023) 22 (12_Supplement): B116.

https://doi.org/10.1158/1535-7163.TARG-23-B116

Published: 01 December 2023

View articletitled, Abstract B116: Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS

Journal Articles

Abstract B115: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

Chandrasekar Iyer, Binghui Li, Trent R Stewart, Tao Wang, Andrew Capen, Rachel Cavitt, Bryan D Anderson, Wayne Bocchinfuso, Gaiying Zhao, Michael J Rodriguez, Santiago Carballares, Andrew Cooke, Robert Bondi, Lee Burns, Lakshmi Kelamangalath, Ross Wallace, Gabrielle Kolakowski, James R Henry, Chong Si

Mol Cancer Ther (2023) 22 (12_Supplement): B115.

https://doi.org/10.1158/1535-7163.TARG-23-B115

Published: 01 December 2023

View articletitled, Abstract B115: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

Journal Articles

An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Ruochen Dong, Ping Chen, Kishore Polireddy, Xiaoqing Wu, Tao Wang, Remya Ramesh, Dan A. Dixon, Liang Xu, Jeffrey Aubé, Qi Chen

Mol Cancer Ther (2020) 19 (11): 2267–2277.

https://doi.org/10.1158/1535-7163.MCT-19-0822

Published: 03 November 2020

View articletitled, An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Includes: Supplementary data

Journal Articles

Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer

Caiyun Wang, Tao Wang, Dacheng Lv, Ling Li, Jinnan Yue, Hong-Zhuan Chen, Lu Xu

Mol Cancer Ther (2019) 18 (12): 2357–2367.

https://doi.org/10.1158/1535-7163.MCT-19-0181

Published: 02 December 2019

View articletitled, Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer

Includes: Supplementary data

Journal Articles

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Mol Cancer Ther (2017) 16 (12): 2677–2688.

https://doi.org/10.1158/1535-7163.MCT-16-0674

Published: 03 December 2017

View articletitled, Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Includes: Supplementary data

Journal Articles

Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma

Haiyang Yu, Yuling Qiu, Xu Pang, Jian Li, Song Wu, Shuangshuang Yin, Lifeng Han, Yi Zhang, Chengyun Jin, Xiumei Gao, Wenwei Hu, Tao Wang

Mol Cancer Ther (2017) 16 (12): 2711–2723.

https://doi.org/10.1158/1535-7163.MCT-17-0498

Published: 03 December 2017

View articletitled, Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma

Includes: Supplementary data

Journal Articles

Abstract B204: A DREAM Challenge to improve prognostic models in patients with metastatic castrate-resistant prostate cancer

Justin Guinney, Tao Wang, Chris Bare, Thea Norman, Brian Bot, Liji Shen, Kimberly Winner, Stephen Friend, Kald Abdallah, Gustavo Stolovitzky, Yang Xie, Fang Liz Zhou, James C. Costello

Mol Cancer Ther (2015) 14 (12_Supplement_2): B204.

https://doi.org/10.1158/1535-7163.TARG-15-B204

Published: 01 December 2015

View articletitled, Abstract B204: A DREAM Challenge to improve prognostic models in patients with metastatic castrate-resistant prostate cancer

Journal Articles

Paclitaxel-Loaded PEG-PE–Based Micellar Nanopreparations Targeted with Tumor-Specific Landscape Phage Fusion Protein Enhance Apoptosis and Efficiently Reduce Tumors

Tao Wang, Shenghong Yang, Leslie A. Mei, Chirag K. Parmar, James W. Gillespie, Kulkarni P. Praveen, Valery A. Petrenko, Vladimir P. Torchilin

Mol Cancer Ther (2014) 13 (12): 2864–2875.

https://doi.org/10.1158/1535-7163.MCT-14-0052

Published: 04 December 2014

View articletitled, Paclitaxel-Loaded PEG-PE–Based Micellar Nanopreparations Targeted with Tumor-Specific Landscape Phage Fusion Protein Enhance Apoptosis and Efficiently Reduce Tumors

Journal Articles

Abstract A24: Targeted synthetic lethal screens to identify acquired vulnerabilities in a novel class of ASCL1-dependent neuroendocrine non-small cell lung cancers

Alexander Augustyn, Mark Borromeo, Tao Wang, Chunli Shao, Patrick Dospoy, Kenneth Huffman, Ryan Carstens, Luc Girard, Carmen Behrens, Ignacio Wistuba, Yang Xie, Jane Johnson, Adi Gazdar, John Minna

Mol Cancer Ther (2013) 12 (5_Supplement): A24.

https://doi.org/10.1158/1535-7163.PMS-A24

Published: 01 May 2014

View articletitled, Abstract A24: Targeted synthetic lethal screens to identify acquired vulnerabilities in a novel class of ASCL1-dependent neuroendocrine non-small cell lung cancers

Journal Articles

Abstract C50: Down-regulation of Bcl2 sensitizes radiation resistance prostate cancer cells to ionizing radiation.

Tao Wang, Robert E. Carraway, Joshua Briggs, Huazhen Chen, Thomas J. FitzGerald

Mol Cancer Ther (2013) 12 (11_Supplement): C50.

https://doi.org/10.1158/1535-7163.TARG-13-C50

Published: 01 November 2013

View articletitled, Abstract C50: Down-regulation of Bcl2 sensitizes radiation resistance prostate cancer cells to ionizing radiation.

Journal Articles

Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Lillian L. Siu, Ghassan Allo, Gregory R. Pond, Tong Zhang, James Ho, Sebastien J. Hotte, Scott A. Laurie, Simron Singh, Eric Winquist, Stephen K. L. Chia, Eric X. Chen, Kelvin K. Chan, Christine Mormont, Susan Quinn, Tao Wang, Ian Taylor, Suzanne Kamel-Reid, Ming S. Tsao, Denis Soulieres

Mol Cancer Ther (2011) 10 (11_Supplement): A50.

https://doi.org/10.1158/1535-7163.TARG-11-A50

Published: 12 November 2011

View articletitled, Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal Articles

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Kenneth Thress, Terry MacIntyre, Haiyun Wang, Dave Whitston, Zhong-Ying Liu, Ethan Hoffmann, Tao Wang, Jeffrey L. Brown, Kevin Webster, Charles Omer, Peter E. Zage, Lizhi Zeng, Patrick A. Zweidler-McKay

Mol Cancer Ther (2009) 8 (7): 1818–1827.

https://doi.org/10.1158/1535-7163.MCT-09-0036

Published: 14 July 2009

View articletitled, Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Includes: Supplementary data

Journal Articles

Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Enrica I. Lerma, Viet-Anh Nguyen, Tao Wang, Alex Tipping, Junia V. Melo, Donald Kufe, David J. Austin, Albert Deisseroth

Mol Cancer Ther (2007) 6 (2): 655–666.

https://doi.org/10.1158/1535-7163.MCT-04-0307

Published: 16 February 2007

View articletitled, Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract B116: Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS

Abstract B115: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma

Abstract B204: A DREAM Challenge to improve prognostic models in patients with metastatic castrate-resistant prostate cancer

Paclitaxel-Loaded PEG-PE–Based Micellar Nanopreparations Targeted with Tumor-Specific Landscape Phage Fusion Protein Enhance Apoptosis and Efficiently Reduce Tumors

Abstract A24: Targeted synthetic lethal screens to identify acquired vulnerabilities in a novel class of ASCL1-dependent neuroendocrine non-small cell lung cancers

Abstract C50: Down-regulation of Bcl2 sensitizes radiation resistance prostate cancer cells to ionizing radiation.

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only